Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1996-05-09
1998-01-20
McKane, Joseph
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514303, 514340, 514341, 514370, 514386, 514393, 514394, 514395, 514397, 544331, 546118, 5462721, 548190, 548193, 548194, 5483027, 5483047, 5483111, A61K 31505, C07D41306
Patent
active
057101590
ABSTRACT:
This invention relates to novel heterocycle compounds including but not amino)propyloxy!isoxazol-5-ylcarbonylamino!-2-(benzyloxycarbonylamino)-pro pionic acid, which are useful as antagonists of the .alpha..sub.v .beta..sub.3 and related integrin receptors, to pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of cell adhesion and the treatment of angiogenic disorders, inflammation, bone degradation, tumors, metastases, thrombosis, and other cell aggregation-related conditions.
REFERENCES:
patent: 5463071 (1995-10-01), Himmelsbach et al.
CA 115:60756 Silver halide . . . ureylene compounds. Nishizeki et al., 1991 .
Batt Douglas Guy
Jadhav Prabhakar Kondaji
Pitts William John
Smallheer Joanne Marie
Voss Matthew Ernst
Ferguson Blair Q.
McKane Joseph
The DuPont Merck Pharmaceutical Company
LandOfFree
Integrin receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Integrin receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Integrin receptor antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-725624